IHC - Her-2/neu c-erb

The IHC – HER2/neu (c-erbB-2) test is an advanced immunohistochemistry (IHC) diagnostic test used to detect HER2 protein overexpression in tissue samples, most commonly in breast cancer. HER2 (Human Epidermal Growth Factor Receptor 2), also known as c-erbB-2, is a protein that helps regulate normal cell growth. When present in excessive amounts, it can cause uncontrolled cell growth and lead to aggressive tumor development.

This test is an essential part of breast cancer diagnosis and classification. It helps determine whether a tumor is HER2-positive or HER2-negative, which directly influences treatment decisions and prognosis. HER2-positive cancers often grow faster but may respond very well to targeted therapies such as trastuzumab and other HER2-directed treatments.

The HER2 IHC test is usually performed along with ER (Estrogen Receptor) and PR (Progesterone Receptor) testing to create a complete breast cancer hormone receptor profile.

Benefits of the Test

The HER2/neu IHC test offers several important benefits:

• Detects HER2 protein overexpression in tumor cells
• Classifies breast cancer subtype accurately
• Identifies eligibility for targeted HER2 therapy
• Helps assess prognosis and tumor aggressiveness
• Supports personalized treatment planning
• Improves treatment success through precision oncology

This test is critical for ensuring patients receive the most effective therapy.

Why Doctors Recommend This Test

Doctors recommend the HER2 IHC test when breast cancer is diagnosed or strongly suspected. It is used to determine whether targeted anti-HER2 medications will be effective.

It is commonly advised for:

• Newly diagnosed breast cancer patients
• Patients with recurrent breast cancer
• Cases requiring detailed tumor profiling
• Patients needing treatment planning guidance
• Assessment of aggressive tumor behavior

The results help oncologists select targeted therapies that improve survival outcomes.

Preparation Before Test

No special preparation is needed from the patient. The test is performed on biopsy or surgically removed tissue samples collected during standard diagnostic procedures.

Normal Reporting Time

The typical turnaround time for the HER2 IHC test is 2 to 4 working days, depending on laboratory processing and sample complexity.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with breast cancer
• Individuals with suspicious breast biopsy findings
• Patients requiring receptor profiling
• Cases of recurrent or metastatic breast carcinoma
• Oncology patients needing targeted therapy evaluation

The HER2/neu (c-erbB-2) IHC test is one of the most important tests in modern breast cancer care. By identifying HER2-positive tumors, it helps doctors offer highly targeted treatments that improve outcomes and provide more personalized cancer management.